Klacid (Clarithromycin)

Clarithromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing peptide chain elongation. This action halts bacterial growth (bacteriostatic) and can be bactericidal at higher concentrations, effectively controlling the infection.

The dosage of Klacid is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Only a qualified healthcare professional should set the appropriate dosing regimen.

Clarithromycin is classified as Pregnancy Category B, indicating no evidence of risk in animal studies and insufficient human data. It may be used during pregnancy only if clearly needed. Limited data exist for breastfeeding; the decision should be made by a healthcare provider weighing benefits and risks.

To order Klacid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Klacid (clarithromycin) offers a broader spectrum against certain Gram‑negative organisms and better tissue penetration compared with older macrolides like erythromycin. It also has a more convenient dosing schedule and fewer drug‑food interactions, making it a preferred choice for many respiratory and skin infections.

Klacid should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the solution from moisture and direct light to maintain stability and potency throughout its shelf life.

Klacid is supplied as an intravenous solution and is administered by a healthcare professional through a vein, typically using an infusion pump or syringe, following aseptic technique and the dosing instructions provided by the prescriber.

Serious risks include severe allergic reactions (anaphylaxis), QT‑interval prolongation leading to potentially life‑threatening arrhythmias, hepatic dysfunction, and Clostridioides difficile‑associated colitis. Patients should be monitored closely for any signs of these adverse events.

Klacid should be avoided in individuals with a known hypersensitivity to macrolide antibiotics, those with a history of significant QT prolongation or ventricular arrhythmias, and patients taking contraindicated medications that may cause dangerous drug interactions.